• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Teligent, Inc.

    6/21/21 6:13:58 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care
    Get the next $TLGT alert in real time by email
    DEFA14A 1 tm2120146d1_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No.   )

     

    Filed by the Registrant x

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

    ¨ Preliminary Proxy Statement
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    x Definitive Additional Materials
    ¨ Soliciting Material Under Rule 14a-12

     

    Teligent, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    x No fee required.
    ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

      1) Title of each class of securities to which transaction applies:

     

      2) Aggregate number of securities to which transaction applies:

     

      3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

     

      4) Proposed maximum aggregate value of transaction:

     

      5) Total fee paid:

     

    ¨ Fee paid previously with preliminary materials.
    ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

     

      1) Amount previously paid:

     

      2) Form, Schedule or Registration Statement No:

     

      3) Filing party:

     

      4) Date Filed:

     

     

     

     

     

     

     

    TELIGENT, INC. ANNOUNCES ADJOURNMENT OF

    ANNUAL MEETING OF STOCKHOLDERS

     

    Scheduled to Reconvene on June 30, 2021

    Company Urgently Encourages Stockholders to Vote

     

    BUENA, NEW JERSEY, June 18, 2021 --  Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented at the Annual Meeting. The Company is adjourning the meeting in order to solicit additional votes to meet the requirements for approval of the proposals presented.

     

    The Special Meeting will be reconvened at 10:00 a.m. Eastern time on June 30, 2021 to allow more opportunity for stockholders to vote on the proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on May 19, 2021. Stockholders will be able to attend the rescheduled Annual Meeting virtually by visiting www.virtualshareholdermeeting.com/TLGT2021.

     

    The record date for determining stockholders eligible to vote on the proposals at the Annual Meeting remains May 17, 2021.

     

    The Company strongly encourages any eligible stockholder that has not yet voted their shares, or provided voting instructions to their broker or other record holder, to do so promptly. No action is required by any stockholder who has previously delivered a proxy and who does not wish to revoke or change that proxy. Shares may be voted via the Internet, by telephone and by mail. For questions relating to the voting of shares or to request additional or misplaced proxy voting materials, contact the Company’s proxy solicitor: MacKenzie Partners, Inc. TOLL-FREE, at 1-800-322-2885 or Collect at 1-212-929-5500 or via email at [email protected].

     

    YOUR PARTICIPATION IS IMPORTANT – PLEASE VOTE TODAY

     

    A copy of the Company’s proxy statement as previously filed with the SEC is available at no charge on the SEC website at www.sec.gov. In addition, copies of the proxy statement and other documents may be obtained free of charge by accessing the Company’s website at www.teligent.com or by contacting the Company’s Corporate Secretary at (856) 776-4632, via email at [email protected] or by mail to Corporate Secretary, Teligent, Inc., 105 Lincoln Avenue, Buena, NJ 08310.

     

     

     

     

    Additional Information

     

    This communication may be deemed to be solicitation material. On September 9, 2020, the Company filed a definitive proxy statement with the SEC in connection with the Special Meeting. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT AND ANY OTHER SOLICITING MATERIALS THAT ARE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSALS TO BE VOTED UPON. The Company’s proxy statement and any other solicitation materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at www.sec.gov and at the investor relations section of the Company’s website at www.teligent.com. The Company, its directors and certain of its officers and employees will be participants in the solicitation of proxies from stockholders in respect of the Special Meeting. The Company has also engaged MacKenzie Partners to aid in the solicitation of proxies. Detailed information regarding the identity of the participants, and their respective interests in the Company by security holdings or otherwise, are set forth in the definitive proxy statement for the Special Meeting. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement.

     

    Forward-Looking Statements

     

    This press release includes “forward-looking statements” that are intended to qualify for the safe harbors from liability provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are statements that could be deemed forward-looking. These statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which the Company operates and the beliefs and assumptions of the Company’s management. Forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “should,” “would,” “believe,” “depends,” “expect,” “goal,” “anticipate,” “forecast,” “project,” “future,” “intend,” “plan,” “estimate,” “target,” “indicate,” “outlook,” and similar expressions of future intent or the negative of such terms. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, these forward-looking statements are based on management’s current beliefs, expectations and assumptions and are subject to risks and uncertainties. These statements are based on the Company’s current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports the Company files with the Securities and Exchange Commission.  Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 outbreak and the effects thereof on the Company’s future performance and results of operations. It is not possible to predict or identify all such risks. There may be additional risks that the Company considers immaterial or which are unknown. You should not rely upon forward-looking statements as predictions of future events.  The forward-looking statements included in this press release speak only as of the date hereof and, subject to any continuing obligations under applicable law or any relevant stock exchange rules, we expressly disclaim any obligation to disseminate, after the date of this document, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.

     

    Contact:

    Philip K. Yachmetz

    Teligent, Inc.

    (856) 776-4632

    www.teligent.com

     

     

     

    Get the next $TLGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLGT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Benesch Joseph

    3 - Teligent, Inc. (0000352998) (Issuer)

    10/8/21 4:31:06 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 3 filed by new insider Lozynski Alyssa

    3 - Teligent, Inc. (0000352998) (Issuer)

    10/7/21 11:09:36 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Celentano John E

    4 - Teligent, Inc. (0000352998) (Issuer)

    7/22/21 5:04:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    SEC Filings

    View All

    SEC Form 25-NSE filed by Teligent, Inc.

    25-NSE - Teligent, Inc. (0000352998) (Subject)

    10/27/21 9:46:36 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Teligent, Inc. (0000352998) (Filer)

    10/15/21 4:35:51 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. filed SEC Form 8-K: Leadership Update

    8-K - Teligent, Inc. (0000352998) (Filer)

    9/27/21 5:02:29 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process

    BUENA, N.J., Oct. 14, 2021 /PRNewswire/ -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several interested parties. The Company expects to consummate a sale of the entire busi

    10/14/21 6:15:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

    –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge

    8/16/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Financials

    Live finance-specific insights

    View All

    Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

    –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge

    8/16/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update

    –Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time –Dial in: (800) 708-4540 US Toll Free Number  (847) 619-6397 US Number  Confirmation Number: 50161966 BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update. "As we prepare for the second half of 2021, we are pleased with the progress being made with respect to remediation, our strengthened capital position, and the recent

    5/25/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Teligent, Inc. (0000352998) (Subject)

    2/16/21 4:30:32 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Teligent, Inc. (0000352998) (Subject)

    2/16/21 12:02:06 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G filed

    SC 13G - Teligent, Inc. (0000352998) (Subject)

    2/16/21 10:39:59 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Leadership Updates

    Live Leadership Updates

    View All

    Teligent Announces Hiring of Chief Financial Officer

    BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT) ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021. Timothy B. Sawyer, President and CEO of the Company, commented, "We are very pleased that Ernie has agreed to join our Teligent team. Over the last several months, we have made key additions to our leadership team, and the appointment of Ernie to the CFO position reflects our commitment to bring in highly talented and experienced individuals who have a strong track record of success. E

    4/15/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors

    BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the Audit and Nominating and Corporate Governance Committees. Mr. Pate leads a family-owned investment firm and serves on the Board of Directors at multiple companies, including Global Step and Advanced Emissions Solutions, Inc. He excels at leading companies through moments of change to drive business objectives and redefine their possibilities for growth.    John Celentano, Chairman of Teligent's Board of Dire

    2/23/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors

    BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries. John Celentano, Chairman of Teligent's Board of Directors, commented on the appointment, stating that "We are excited to have Bill join Teligent's Board of Directors. He is a strategic leader with extensive experience in helping businesses transform and

    2/16/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care